Skip to content

Motion-model Ultrasound Localization Microscopy (mULM) for Diagnostics and Therapy Monitoring in Breast Carcinoma

Motion-model Ultrasound Localization Microscopy (mULM) for Diagnostics and Therapy Monitoring in Breast Carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00023954
Enrollment
74
Registered
2021-01-07
Start date
2021-01-10
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C50

Interventions

Group 1: Study Part A: Patients with primary breast carcinoma will receive ultrasound imaging to assess tumor size, location, and structure in the form of B-mode ultrasound, elastography, and contrast

Sponsors

Klinik für Gynäkologie und Geburtshilfe RWTH Aachen
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. patients with histologically confirmed primary breast carcinoma including all intrinsic subtypes (study part A and B) and patients with high-grade suspicion of primary breast carcinoma (study part C). 2. treatment with neoadjuvant chemotherapy (study part A and B) 3. written informed consent 4. subjects who are legally competent and mentally able to comply with the instructions of the study personnel

Exclusion criteria

Exclusion criteria: 1. minority 2. hypersensitivity / allergy to ultrasound contrast agent or its components sulfur hexafluoride, macrogol 4000, colfosceril stearate, 1-(1,2-dipalmitoyl-3-sn-phosphatidyl)glycerol sodium salt palmitic acid 3. right-left shunt 4. signs of cardiovascular instability 5. acute endocarditis 6. artificial heart valves 7. acute systemic inflammation and/or sepsis 8. overactive coagulation status and/or recent thromboembolism 9. end-stage renal or hepatic disease 10. severe pulmonary hypertension (pulmonary arterial pressure > 90 mmHG) 11. uncontrolled systemic hypertension 12. acute respiratory distress syndrome 13. pregnant women 14. persons who are institutionalized by administrative or judicial order 15. persons who are in a dependent or employment relationship with the sponsor or investigator 16. alcohol and drug abuse 17. expected non-compliance

Design outcomes

Primary

MeasureTime frame
The goal of this project is to adapt the mULM to clinical application to study the discrimination of benign and malignant breast cancer tumors and the prediction and monitoring of breast cancer responses to neoadjuvant chemotherapy in an exploratory patient study.

Countries

Germany

Contacts

Public ContactElmar Stickeler

Klinik für Gynäkologie und Geburtshilfe Uniklinik RWTH Aachen

estickeler@ukaachen.de02418088400

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026